NCT01453218View on ClinicalTrials.gov

Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Renal Insufficiency
Interventions
DRUG

ATeGe-Fresenius

Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels

Trial Locations (1)

08035

Department of HPB Surgery and Transplants, Hospital Vall d´Hebron, Barcelona

All Listed Sponsors
collaborator

Hospital Universitari Vall d'Hebron Research Institute

OTHER

lead

Hospital Vall d'Hebron

OTHER

NCT01453218 - Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction | Biotech Hunter | Biotech Hunter